Karl Mann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Karl Mann has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Bernhard Croissant
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Mannheim, University of Heidelberg, Germany
5 shared publications- Derik Hermann
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Germany
4 shared publications - Andreas Heinz
Department of Psychiatry and Psychotherapy, Technische Universität Dresden
3 shared publications B. Croissant
Akademisches Lehrkrankenhaus
3 shared publications- Michael N. Smolka
Department of Psychiatry and Psychotherapy, Technische Universität Dresden
3 shared publications Alexander Diehl
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Mannheim, University of Heidelberg, Germany
2 shared publications
Latest Publications
- 12 December 2012
- Published by Wiley in Addiction Biology
- Vol. 18 (6) , 937-946
Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study
The results of placebo‐controlled trials (RCTs) with acamprosate or naltrexone vary substantially. Those differences have been attributed to differing patient characteristics, recruitment strategies, treatment settings and remuneration systems. We tested these assumptions by comparing a new double–blind, placebo‐controlled randomized trial conducted in Germany (called PREDICT Study) with data from the US COMBINE Study. PREDICT was designed according to the protocol of the COMBINE Study. A total of 426 alcohol‐dependent patients were compared to 459 COMBINE Study patients corresponding to the treatment cells in PREDICT. All patients received acamprosate, naltrexone or placebo for 3 months (PREDICT) or 4 months (COMBINE). Biweekly manualized ‘medical management’ to enhance compliance was delivered in both studies. Time until the first occurrence of heavy drinking was the main outcome measure. PREDICT found neither acamprosate nor naltrexone to supply any additional benefit compared with placebo, which is at variance with a positive naltrexone effect being reported in the COMBINE Study. A secondary comparison between both studies showed better overall treatment outcomes in PREDICT, although these patients had been more severely affected than their COMBINE counterparts. The divergence in results may be attributable to basic differences in the treatment environments (such as in‐patient pre‐treatment versus primary outpatient care). We suggest that identically designed RCTs conducted in different parts of the world may help improve the external validity of RCTs. This approach could be called ‘comparative efficacy research’.
- 12 December 2012
- Published by Wiley in Addiction Biology
- Vol. 18 (6) , 937-946
Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study
The results of placebo‐controlled trials (RCTs) with acamprosate or naltrexone vary substantially. Those differences have been attributed to differing patient characteristics, recruitment strategies, treatment settings and remuneration systems. We tested these assumptions by comparing a new double–blind, placebo‐controlled randomized trial conducted in Germany (called PREDICT Study) with data from the US COMBINE Study. PREDICT was designed according to the protocol of the COMBINE Study. A total of 426 alcohol‐dependent patients were compared to 459 COMBINE Study patients corresponding to the treatment cells in PREDICT. All patients received acamprosate, naltrexone or placebo for 3 months (PREDICT) or 4 months (COMBINE). Biweekly manualized ‘medical management’ to enhance compliance was delivered in both studies. Time until the first occurrence of heavy drinking was the main outcome measure. PREDICT found neither acamprosate nor naltrexone to supply any additional benefit compared with placebo, which is at variance with a positive naltrexone effect being reported in the COMBINE Study. A secondary comparison between both studies showed better overall treatment outcomes in PREDICT, although these patients had been more severely affected than their COMBINE counterparts. The divergence in results may be attributable to basic differences in the treatment environments (such as in‐patient pre‐treatment versus primary outpatient care). We suggest that identically designed RCTs conducted in different parts of the world may help improve the external validity of RCTs. This approach could be called ‘comparative efficacy research’.
- 12 November 2009
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 134 (47) , 2411
Kontrolliertes Trinken bei Personen mit alkoholbezogenen Störungen (Missbrauch, Abhängigkeit) – contra
Suchtprävention - Alkoholmissbrauch - kontrolliertes Trinken - Verhaltenstherapie addiction prevention - alcohol abuse - controlled drinking - behavioral therapy
- 12 November 2009
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 134 (47) , 2411
Kontrolliertes Trinken bei Personen mit alkoholbezogenen Störungen (Missbrauch, Abhängigkeit) – contra
Suchtprävention - Alkoholmissbrauch - kontrolliertes Trinken - Verhaltenstherapie addiction prevention - alcohol abuse - controlled drinking - behavioral therapy
- 17 October 2009
- Published by Springer Nature in Der Nervenarzt
- Vol. 80 (11) , 1293-1301
Suchterkrankungen in der Lebensspanne
- 17 October 2009
- Published by Springer Nature in Der Nervenarzt
- Vol. 80 (11) , 1293-1301
Suchterkrankungen in der Lebensspanne
- 28 May 2009
- Published by Springer Nature in Der Nervenarzt
- Vol. 80 (9) , 1085-1092
Behandlungserfolg nach qualifiziertem Alkoholentzug
- 28 May 2009
- Published by Springer Nature in Der Nervenarzt
- Vol. 80 (9) , 1085-1092
Behandlungserfolg nach qualifiziertem Alkoholentzug
- 25 March 2009
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 33 (4) , 674-683
Searching for Responders to Acamprosate and Naltrexone in Alcoholism Treatment: Rationale and Design of thePredict Study
Background: Alcoholism represents a major public health issue and treating alcohol dependent patients remains an imminent challenge. Evidence based psychotherapies and pharmacotherapies are available. However, when administered to heterogeneous populations of patients effect sizes are only modest. We present the rationale and design of a double‐blind randomized trial comparing acamprosate, naltrexone, and placebo. Additionally we subtype patients on the basis of biological and psychometric measures and explore their treatment response to both acamprosate and naltrexone. According to our initial hypothesis, the “relief drinker/craver” is an endophenotype associated with glutamatergic dysfunction who responds to acamprosate. The “reward drinker/craver” is mainly associated with alterations in the dopaminergic and opioidergic system and responds to naltrexone.Methods: The study is planned for 430 patients (2:2:1 for both drugs and placebo) over 12 weeks of medication. All receive manualized counselling to improve compliance (Medical Management) which is extended to 6 months. Subtyping is primarily done using the acoustic startle reflex, functional magnetic resonance imaging, positron emission tomography (in a subset of patients), and the Inventory of Drinking Situations. Relapsers will be re‐randomized into a second study where additional psychotherapy (Cognitive Behavioral Intervention) is used in a stepped care approach. Genotyping and additional analyses such as health economy are being done as well. The study follows the assessment methods, treatments, and medications used in the U.S. based COMBINE study, which will allow for a direct comparison between this U.S. study trial and a study performed in Europe.
- 25 March 2009
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 33 (4) , 674-683
Searching for Responders to Acamprosate and Naltrexone in Alcoholism Treatment: Rationale and Design of thePredict Study
Background: Alcoholism represents a major public health issue and treating alcohol dependent patients remains an imminent challenge. Evidence based psychotherapies and pharmacotherapies are available. However, when administered to heterogeneous populations of patients effect sizes are only modest. We present the rationale and design of a double‐blind randomized trial comparing acamprosate, naltrexone, and placebo. Additionally we subtype patients on the basis of biological and psychometric measures and explore their treatment response to both acamprosate and naltrexone. According to our initial hypothesis, the “relief drinker/craver” is an endophenotype associated with glutamatergic dysfunction who responds to acamprosate. The “reward drinker/craver” is mainly associated with alterations in the dopaminergic and opioidergic system and responds to naltrexone.Methods: The study is planned for 430 patients (2:2:1 for both drugs and placebo) over 12 weeks of medication. All receive manualized counselling to improve compliance (Medical Management) which is extended to 6 months. Subtyping is primarily done using the acoustic startle reflex, functional magnetic resonance imaging, positron emission tomography (in a subset of patients), and the Inventory of Drinking Situations. Relapsers will be re‐randomized into a second study where additional psychotherapy (Cognitive Behavioral Intervention) is used in a stepped care approach. Genotyping and additional analyses such as health economy are being done as well. The study follows the assessment methods, treatments, and medications used in the U.S. based COMBINE study, which will allow for a direct comparison between this U.S. study trial and a study performed in Europe.
- 8 June 2008
- Published by Elsevier in Addictive Behaviors
- Vol. 33 (10) , 1276-1281
Modifications of the Obsessive Compulsive Drinking Scale (OCDS-G) for use in longitudinal studies
- 8 June 2008
- Published by Elsevier in Addictive Behaviors
- Vol. 33 (10) , 1276-1281
Modifications of the Obsessive Compulsive Drinking Scale (OCDS-G) for use in longitudinal studies
- 14 July 2007
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 257 (6) , 344-351
Alcoholism in women: is it different in onset and outcome compared to men?
Onset and course of alcohol dependence show gender related differences (telescoping effect) suggesting that women are more vulnerable to chronic alcohol consumption. This raises the question whether the differences are associated with a different treatment outcome as well. We hypothesized, that alcohol dependent women with a telescoping course show a less favourable treatment outcome compared to men. We investigated 212 alcohol dependent patients; matching 106 consecutively admitted women with 106 men drawn from a total sample of 343 male patients. The treatment program consisted of a 6 week inpatient treatment and 12 months of outpatient aftercare. We assessed milestone variables in development and course of alcoholism and carried out standardized diagnostic tests, physical and blood examinations to evaluate the course of the disease and treatment outcome. Overall, we confirm the telescoping effect, a faster progression in the course of alcoholism (developmental events and adverse consequences) in women compared to men (“telescoping effect”). However, despite the telescoping effect treatment outcome was similar in women and men. During the inpatient treatment program no alcohol relapse occurred. Throughout the 12 months outpatient treatment we found no significant differences in the survival analysis between women (283.29 ± 11.26 days) and men (284.72 ± 12.16 days). At the end of the 12 months both groups had an abstinence rate of approximately 50% and a drop-out rate of 33%.
- 14 July 2007
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 257 (6) , 344-351
Alcoholism in women: is it different in onset and outcome compared to men?
Onset and course of alcohol dependence show gender related differences (telescoping effect) suggesting that women are more vulnerable to chronic alcohol consumption. This raises the question whether the differences are associated with a different treatment outcome as well. We hypothesized, that alcohol dependent women with a telescoping course show a less favourable treatment outcome compared to men. We investigated 212 alcohol dependent patients; matching 106 consecutively admitted women with 106 men drawn from a total sample of 343 male patients. The treatment program consisted of a 6 week inpatient treatment and 12 months of outpatient aftercare. We assessed milestone variables in development and course of alcoholism and carried out standardized diagnostic tests, physical and blood examinations to evaluate the course of the disease and treatment outcome. Overall, we confirm the telescoping effect, a faster progression in the course of alcoholism (developmental events and adverse consequences) in women compared to men (“telescoping effect”). However, despite the telescoping effect treatment outcome was similar in women and men. During the inpatient treatment program no alcohol relapse occurred. Throughout the 12 months outpatient treatment we found no significant differences in the survival analysis between women (283.29 ± 11.26 days) and men (284.72 ± 12.16 days). At the end of the 12 months both groups had an abstinence rate of approximately 50% and a drop-out rate of 33%.
- 1 June 2007
- Published by Springer Nature in Psychiatrie und Psychotherapie
- Vol. 3 (2) , 51-56
New approaches in the diagnostics and the treatment of alcohol problems
- 1 June 2007
- Published by Springer Nature in Psychiatrie und Psychotherapie
- Vol. 3 (2) , 51-56
New approaches in the diagnostics and the treatment of alcohol problems
- 24 May 2007
- Published by Springer Nature in Der Nervenarzt
- Vol. 79 (1) , 80-85
Längsschnittuntersuchung alkoholauffälliger Mitarbeiter in einem Großbetrieb nach werksärztlicher Kurzintervention
- 24 May 2007
- Published by Springer Nature in Der Nervenarzt
- Vol. 79 (1) , 80-85
Längsschnittuntersuchung alkoholauffälliger Mitarbeiter in einem Großbetrieb nach werksärztlicher Kurzintervention